Cable Viewer

Currently released so far... 12433 / 251,287

### Browse latest releases

2010/11 2010/12 2011/01 2011/02 2011/03 2011/04 2011/05
2010/11/28 2010/11/29 2010/11/30
2010/12/01 2010/12/02 2010/12/03 2010/12/04 2010/12/05 2010/12/06 2010/12/07 2010/12/08 2010/12/09 2010/12/10 2010/12/11 2010/12/12 2010/12/13 2010/12/14 2010/12/15 2010/12/16 2010/12/17 2010/12/18 2010/12/19 2010/12/20 2010/12/21 2010/12/22 2010/12/23 2010/12/24 2010/12/25 2010/12/26 2010/12/27 2010/12/28 2010/12/29 2010/12/30
2011/01/01 2011/01/02 2011/01/04 2011/01/05 2011/01/07 2011/01/09 2011/01/10 2011/01/11 2011/01/12 2011/01/13 2011/01/14 2011/01/15 2011/01/16 2011/01/17 2011/01/18 2011/01/19 2011/01/20 2011/01/21 2011/01/22 2011/01/23 2011/01/24 2011/01/25 2011/01/26 2011/01/27 2011/01/28 2011/01/29 2011/01/30 2011/01/31
2011/02/01 2011/02/02 2011/02/03 2011/02/04 2011/02/05 2011/02/06 2011/02/07 2011/02/08 2011/02/09 2011/02/10 2011/02/11 2011/02/12 2011/02/13 2011/02/14 2011/02/15 2011/02/16 2011/02/17 2011/02/18 2011/02/19 2011/02/20 2011/02/21 2011/02/22 2011/02/23 2011/02/24 2011/02/25 2011/02/26 2011/02/27 2011/02/28
2011/03/01 2011/03/02 2011/03/03 2011/03/04 2011/03/05 2011/03/06 2011/03/07 2011/03/08 2011/03/09 2011/03/10 2011/03/11 2011/03/13 2011/03/14 2011/03/15 2011/03/16 2011/03/17 2011/03/18 2011/03/19 2011/03/20 2011/03/21 2011/03/22 2011/03/23 2011/03/24 2011/03/25 2011/03/26 2011/03/27 2011/03/28 2011/03/29 2011/03/30 2011/03/31
2011/04/01 2011/04/02 2011/04/03 2011/04/04 2011/04/05 2011/04/06 2011/04/07 2011/04/08 2011/04/09 2011/04/10 2011/04/11 2011/04/12 2011/04/13 2011/04/14 2011/04/15 2011/04/16 2011/04/17 2011/04/18 2011/04/19 2011/04/20 2011/04/21 2011/04/22 2011/04/23 2011/04/24 2011/04/25 2011/04/26 2011/04/27 2011/04/28 2011/04/29 2011/04/30
2011/05/01 2011/05/02 2011/05/03 2011/05/04

### Browse by creation date

66 72 73 75 79 85 86 87 88 89 90 91 92 93 96 97 00 01 02 03 04 05 06 07 08 09 10
1966/12
1972/02 1972/08
1973/04
1975/03
1979/08
1985/03 1985/06
1986/05
1987/06
1988/01
1989/12
1990/01 1990/07 1990/08 1990/10
1991/05
1992/01 1992/06 1992/12
1993/10
1996/11
1997/12
2000/05 2000/06 2000/09 2000/11
2001/02 2001/03 2001/06 2001/07 2001/09 2001/10 2001/11
2002/01 2002/02 2002/03 2002/04 2002/07 2002/08 2002/09 2002/11
2003/01 2003/02 2003/03 2003/04 2003/05 2003/06 2003/07 2003/08 2003/09 2003/10 2003/11 2003/12
2004/01 2004/02 2004/03 2004/04 2004/05 2004/06 2004/07 2004/08 2004/09 2004/10 2004/11 2004/12
2005/01 2005/02 2005/03 2005/04 2005/05 2005/06 2005/07 2005/08 2005/09 2005/10 2005/11 2005/12
2006/01 2006/02 2006/03 2006/04 2006/05 2006/06 2006/07 2006/08 2006/09 2006/10 2006/11 2006/12
2007/01 2007/02 2007/03 2007/04 2007/05 2007/06 2007/07 2007/08 2007/09 2007/10 2007/11 2007/12
2008/01 2008/02 2008/03 2008/04 2008/05 2008/06 2008/07 2008/08 2008/09 2008/10 2008/11 2008/12
2009/01 2009/02 2009/03 2009/04 2009/05 2009/06 2009/07 2009/08 2009/09 2009/10 2009/11 2009/12
2010/01 2010/02

### Browse by origin

A B C D F G H I J K L M N O P Q R S T U V W Y Z
Embassy Athens Embassy Asuncion Embassy Astana Embassy Asmara Embassy Ashgabat Embassy Apia Embassy Ankara Embassy Amman Embassy Algiers Embassy Addis Ababa Embassy Accra Embassy Abuja Embassy Abu Dhabi Embassy Abidjan Consulate Auckland Consulate Amsterdam Consulate Adana American Institute Taiwan, Taipei
Embassy Bujumbura Embassy Buenos Aires Embassy Budapest Embassy Bucharest Embassy Brussels Embassy Bridgetown Embassy Bratislava Embassy Brasilia Embassy Bogota Embassy Bishkek Embassy Bern Embassy Berlin Embassy Belmopan Embassy Belgrade Embassy Beirut Embassy Beijing Embassy Banjul Embassy Bangkok Embassy Bandar Seri Begawan Embassy Bamako Embassy Baku Embassy Baghdad Consulate Barcelona
Embassy Copenhagen Embassy Conakry Embassy Colombo Embassy Chisinau Embassy Caracas Embassy Canberra Embassy Cairo Consulate Curacao Consulate Ciudad Juarez Consulate Chennai Consulate Casablanca Consulate Cape Town Consulate Calgary
Embassy Dushanbe Embassy Dublin Embassy Doha Embassy Djibouti Embassy Dili Embassy Dhaka Embassy Dar Es Salaam Embassy Damascus Embassy Dakar Consulate Dubai
Embassy Freetown
Embassy Guatemala Embassy Gaborone Consulate Guayaquil Consulate Guadalajara
Embassy Helsinki Embassy Harare Embassy Hanoi Consulate Ho Chi Minh City Consulate Hermosillo Consulate Hamilton Consulate Hamburg Consulate Halifax
Iran RPO Dubai Embassy Islamabad Consulate Istanbul
Embassy Jakarta Consulate Jerusalem Consulate Jeddah
Embassy Kyiv Embassy Kuwait Embassy Kuala Lumpur Embassy Kinshasa Embassy Kingston Embassy Kigali Embassy Khartoum Embassy Kathmandu Embassy Kampala Embassy Kabul Consulate Kolkata
Embassy Luxembourg Embassy Luanda Embassy London Embassy Ljubljana Embassy Lisbon Embassy Lima Embassy Lilongwe Embassy La Paz Consulate Lahore Consulate Lagos
Mission USOSCE Mission USNATO Mission UNESCO Embassy Muscat Embassy Moscow Embassy Montevideo Embassy Monrovia Embassy Minsk Embassy Mexico Embassy Mbabane Embassy Maputo Embassy Manila Embassy Manama Embassy Managua Embassy Malabo Embassy Madrid Consulate Munich Consulate Mumbai Consulate Montreal Consulate Monterrey Consulate Milan Consulate Melbourne
Embassy Nicosia Embassy New Delhi Embassy Ndjamena Embassy Nassau Embassy Nairobi Consulate Naples Consulate Naha
Embassy Ouagadougou Embassy Ottawa Embassy Oslo
Embassy Pristina Embassy Pretoria Embassy Prague Embassy Port Of Spain Embassy Port Louis Embassy Port Au Prince Embassy Phnom Penh Embassy Paris Embassy Paramaribo Embassy Panama Consulate Peshawar
Embassy Quito Consulate Quebec
REO Basrah Embassy Rome Embassy Riyadh Embassy Riga Embassy Reykjavik Embassy Rangoon Embassy Rabat Consulate Rio De Janeiro Consulate Recife
Secretary of State Embassy Suva Embassy Stockholm Embassy Sofia Embassy Skopje Embassy Singapore Embassy Seoul Embassy Sarajevo Embassy Santo Domingo Embassy Santiago Embassy Sanaa Embassy San Salvador Embassy San Jose Consulate Strasbourg Consulate St Petersburg Consulate Shenyang Consulate Shanghai Consulate Sao Paulo
Embassy Tunis Embassy Tripoli Embassy Tokyo Embassy The Hague Embassy Tel Aviv Embassy Tehran Embassy Tegucigalpa Embassy Tbilisi Embassy Tashkent Embassy Tallinn Consulate Toronto Consulate Tijuana
USUN New York USEU Brussels US Office Almaty US Mission Geneva US Interests Section Havana US Delegation, Secretary UNVIE Embassy Ulaanbaatar
Embassy Vilnius Embassy Vienna Embassy Vatican Embassy Valletta Consulate Vladivostok Consulate Vancouver
Embassy Windhoek Embassy Wellington Embassy Warsaw
Embassy Yerevan Embassy Yaounde
Embassy Zagreb

### Browse by tag

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
AORC AF AR ASEC AEMR AMGT AE ABLD AL AJ AU AO AFIN ASUP AUC APECO AM AG APER AGMT AMED ADCO AS AID AND AMBASSADOR ARM ABUD AODE AMG ASCH ARF ASEAN ADPM ACABQ AFFAIRS ATRN ASIG AA AC ACOA ANET APEC AQ AY ASEX ATFN AFU AER ALOW AZ APCS AVERY ASECKFRDCVISKIRFPHUMSMIGEG AN AGRICULTURE AMCHAMS AINF AGAO AIT AORL ACS AFSI AFSN ACBAQ AFGHANISTAN ADANA AX AECL AADP AMEX ACAO AORG ADM AGR AROC
BL BR BO BE BK BY BA BILAT BU BM BEXP BF BTIO BC BBSR BMGT BTIU BG BD BWC BH BIDEN BB BT BRUSSELS BP BX BN
CD CH CM CU CBW CS CVIS CF CIA CLINTON CASC CE CR CG CO CJAN CY CMGT CA CI CN CPAS CAN CDG CW CONDOLEEZZA CT CIC CIDA CSW CACM CB CODEL COUNTERTERRORISM CTR COUNTER CWC CONS CITEL CV CFED CBSA CITT CDC COM COE COUNTRY CLEARANCE CDB CKGR CACS CARSON CROS CAPC CHR CL CICTE CIS CNARC CJUS CEUDA CLMT CAC COPUOS CBC CBE CARICOM CTM CVR
DR DPRK DEPT DA DJ DEA DTRA DOMESTIC DHS DAO DCM DO DE DEAX DOE DK DS DISENGAGEMENT DOD DEFENSE
EAGR EAIR ECON ECPS ETRD EUN ENRG EINV EMIN EU EFIN EREL EG EPET ENGY ETTC EIND ECIN EAID ELAB EC EZ ENVR ELTN ELECTIONS ER EINT ES EWWT ENIV EAP EFIS ERD ENERG EAIDS ECUN EI EINVEFIN EN EUC EINVETC ENGR ET ETRDEINVECINPGOVCS ECONOMY EUMEM ESA EXTERNAL EINVECONSENVCSJA EINN EEPET ENVI EFTA ESENV ECINECONCS EPA ECONOMIC ETRA EIAR EUREM ETRC EXBS ELN ECA EK ECONEFIN ETC ETRDECONWTOCS EUNCH ECIP EINDETRD EUR ENNP EXIM ERNG EFINECONCS ETRDEINVTINTCS ETRO EDU ETRN EFIM EAIG EURN ECONCS ECONOMICS
FR FREEDOM FTA FI FOR FJ FTAA FARC FINANCE FDA FAC FBI FAO FM FMLN FO FISO FOREIGN FOI FAS FINR
GM GE GG GZ GOV GT GR GAERC GV GH GA GY GOI GTIP GCC GERARD GAZA GTMO GL GLOBAL GANGS GF
HO HA HILLARY HUMAN HR HURI HEBRON HU HK HUMOR HSTC HI HYMPSK
IS ICRC IN IR IZ IT INRB IAEA ICAO ITALY ITALIAN IRAQI IC IL ID IV IMO INMARSAT IQ IRAJ IO ICTY IPR IWC ILC INTELSAT IBRD IMF IRC IRS ILO ITU IDA IAHRC ICJ ITRA ISRAELI ITF IACI IDP ICTR IIP IA IF IZPREL IGAD INTERPOL INTERNAL ISRAEL ISLAMISTS INDO ITPHUM ITPGOV IBET IEFIN INR INRA INRO IEA
JA JAMES JO JM JOSEPH JP JOHNNIE JOHN JUS
KSCA KUNR KHLS KAWK KISL KPAO KSPR KGHG KPKO KDEM KNNP KN KS KPAL KACT KCRM KDRG KJUS KGIC KRAD KU KTFN KV KMDR KWBG KSUM KSEP KCOR KHIV KG KGCC KTIP KIRF KE KIPR KMCA KCIP KTIA KAWC KBCT KVPR KPLS KREL KCFE KOMC KFRD KWMN KTDB KPRP KMFO KZ KVIR KOCI KMPI KFLU KSTH KCRS KTBT KIRC KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG KFLO KSTC KFSC KFTFN KIDE KOLY KMRS KICA KCGC KSAF KRVC KVRP KCOM KAID KTEX KICC KNSD KBIO KOMS KGIT KHDP KNEI KTRD KWNM KRIM KSEO KR KWAC KMIG KIFR KBTR KTER KDDG KPRV KPAK KO KRFD KHUM KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG KREC KCFC KLIG KWMNCS KSEC KPIN KPOA KWWMN KX KCMR KPWR KCHG KRGY KSCI KNAR KFIN KBTS KPAONZ KNUC KNPP KDEMAF KNUP KNNPMNUC KERG KCRCM KWMM KPAI KHSA KTLA KRCM KCSY KSAC KID KOM KMOC KESS KDEV KJUST
LE LY LI LH LAB LU LG LOG LTTE LA LO LABOR LT
MARR MOPS MX MASS MNUC MCAP MO MU ML MA MTCRE MY MOPPS MASC MIL MR MTS MLS MILI MK MEPP MD MAR MP MTRE MCC MZ MDC MRCRE MV MI MEPN MAPP MEETINGS MAS MTCR MG MEPI MT MEDIA MASSMNUC MQADHAFI MPOS MAPS MARAD MC MIK MUCN MILITARY MERCOSUR MW
NZ NL NATO NO NI NU NATIONAL NG NP NPT NPG NS NA NSG NAFTA NC NH NE NSF NSSP NDP NORAD NK NEW NR NASA NT NIPP NAR NGO NW NV NATOPREL NPA NRR NSC NSFO NZUS
OTRA OVIP OEXC OIIP OSAC OPRC OVP OFFICIALS OAS OREP OPIC OSCE OECD OSCI OFDP OPDC OIC OFDA ODIP OBSP ON OCII OES OPCW OPAD OIE OHUM OCS OMIG OTR
PGOV PREL PARM PHUM PREF PTER PINS PK PINR PROP PBTS PKFK PL PE PSOE PEPR PM PAK POLITICS POL PHSA PPA PA PBIO PINT PF PFOR PHALANAGE PARTY PNAT POLINT PRAM PMAR PG PAO PROG PRELP PCUL PSEPC PGIV PO PREFA PALESTINIAN PGOVLO PGOVE PLN PINF PAS PDEM PHUMPGOV PNG PHUH PMIL POGOV PHUMPREL PHUS PRL PGOC PNR PGGV PROV PHUMBA PEL PECON POV PSA PREO PAHO PP PSI PINL PU PARMS PRGOV PAIGH POLITICAL PARTIES POSTS PTBS PORG PUNE POLICY PDOV PCI PGOVSMIGKCRMKWMNPHUMCVISKFRDCA PBT PS PY PTERE PGOF
QA
RS RO RU RW REGION RIGHTS RSP ROBERT RP RICE REACTION RCMP RFE RM RIGHTSPOLMIL RF ROOD RUPREL RSO RELATIONS REPORT
SENV SZ SOCI SNAR SP SCUL SU SY SA SO SF SMIG SW STEINBERG SG SIPRS SR SI SPCE SN SYRIA SL SC SHI SNARIZ SIPDIS SPCVIS SH SOFA SK ST SEVN SYR SHUM SAN SNARCS SAARC SARS SEN SANC SCRS SENVKGHG SNARN SWE SSA
TPHY TW TS TU TX TRGY TIP TSPA TSPL TBIO TNGD TI TFIN TC TRSY TZ TINT TT TF TN TERRORISM TP TURKEY TD TH TBID TL TV TAGS TK TR THPY TO
UNGA UNSC UNCHR UK US UP UNEP UNMIK UN UAE UZ UG UNESCO UNHRC USTR UNHCR UY USOAS UNDC UNCHC UNO UNFICYP USEU UNDP UNODC UNCND UNAUS UNCHS UV USUN USNC UNIDROIT UNCSD UNICEF UE UNC USPS UNDESCO UNPUOS USAID UNVIE
VE VT VZ VTPREL VM VN VTIZ VAT VC VTEG VI
WMO WTRQ WB WI WWARD WA WBG WITH WHA WTO WMD WTRO WIPO WHO WS WHTI WEU WZ WFP
XB XG XT XH XA XM XF XE XR XK XL XW XY XS XX XV XD XTAG XQ XU XZ XC XI
YM YE YI YMCS
ZI ZP ZR ZO ZF ZANU ZOELLICK ZU ZL ZEALAND ZN ZB ZA ZK ZJ

### Browse by classification

CONFIDENTIAL CONFIDENTIAL//NOFORN SECRET SECRET//NOFORN UNCLASSIFIED UNCLASSIFIED//FOR OFFICIAL USE ONLY

### Community resources

Follow us on Twitter Check our Reddit Twitter this Digg this page Contact us on IRC

courage is contagious

### Viewing cable 06OTTAWA2021, POTENTIAL FOR IPR PROGRESS: CANADA'S PROPOSED

If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs
Understanding cables
Every cable message consists of three parts:

- The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
- The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
- The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.

To understand the justification used for the classification of each cable, please use this WikiSource article as reference.
Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #06OTTAWA2021.

Reference ID | Created | Released | Classification | Origin
--- | --- | --- | --- | ---
06OTTAWA2021 | 2006-06-29 19:07 | 2011-04-28 00:12 | UNCLASSIFIED//FOR OFFICIAL USE ONLY | Embassy Ottawa

`

    VZCZCXRO5122
    RR RUEHGA RUEHHA RUEHQU RUEHVC
    DE RUEHOT #2021/01 1801957
    ZNR UUUUU ZZH
    R 291957Z JUN 06
    FM AMEMBASSY OTTAWA
    TO RUEHC/SECSTATE WASHDC 3024
    INFO RUCNCAN/ALL CANADIAN POSTS COLLECTIVE
    RUCPDOC/DEPT OF COMMERCE WASHDC

` `

    UNCLAS SECTION 01 OF 02 OTTAWA 002021

    SIPDIS

    SENSITIVE
    SIPDIS

    STATE PASS TO USTR FOR GARDE, ESPINEL, CHANDLER
    STATE PASS TO USDOC FOR GWORD, JBOGER
    STATE PASS TO USPTO FOR MKEPLINGER

    E.O. 12958: N/A
    TAGS: KIPR ECON TBIO CA
    SUBJECT: POTENTIAL FOR IPR PROGRESS:  CANADA'S PROPOSED
    DATA PROTECTION REGULATIONS

    REF: A. OTTAWA 1701

         ¶B. OTTAWA 1317

    ¶1.  (SBU)  Summary:  The GOC has proposed a two-regulation
    package (significantly different from its 2004 proposal)
    consisting of data protection for the innovative
    pharmaceutical industries and "Patented Medicines (Notice of
    Compliance)" for the generic drug industries, a combination
    designed to force compromise between the two sectors.
    Although the innovative pharmaceutical industry organizations
    PhRMA and Rx&D have minor complaints which they hope to have
    addressed in the final regulations (the comment period ends
    July 17), in general the package seems to be a positive
    development for IPR protection in Canada.  In particular, the
    Data Protection regulation is designed to bring Canada into
    compliance with its international obligations to provide
    protection for proprietary data belonging to patent-holding
    companies, something that the Embassy has been encouraging.
    Assuming the proposed rules are finalized, industry observes
    believe that this will be a step forward for Canada's
    protection of IPR and will directly address one complaint
    from the last two Special 301 Reports on Canada.  End Summary.

    The Regulations
    ---------------

    ¶2.  (U)  (SBU)  The Patented Medicines (Notice of Compliance)
    or PMNOC regulation and, to a lesser extent, the Data
    Protection regulation are complex, and we would welcome
    insights from USG experts.  The data protection regulation
    can be found at
    canadagazette.gc.ca/partI/2006/20060617/html/ regle4-e.html
    The PMNOC regulation can be found at
    canadagazette.gc.ca/partI/2006/20060617/html/ regle6-e.html
    Our initial perusal and conversations with contacts have
    provided the following information.

    ¶3.  (SBU) The draft Data Protection regulation stipulates
    that a secondary manufacturer (usually a generic) cannot file
    a new drug submission on the basis of a direct or indirect
    comparison between the new drug and an innovative drug until
    six years after the first notice of compliance was issued to
    the innovator.  The submission will not be approved until at
    least eight years after the first notice of compliance was
    issued.  This data protection period of eight years compares
    favorably to the U.S. "five plus three" period.  (Comment:
    One observer joked to us that now Canada would have better
    data protection than the United States and that the
    innovative industry may start to use this as leverage to
    argue for better data protection in the United States.  End
    comment.)  Both the Canadian industry group Rx&D and PhRMA in
    the United States are preparing comments to submit to Health
    Canada.  From discussions with industry contacts, we believe
    the industry comments will focus on requests for
    clarification, particularly surrounding the transitional
    language that will determine how drug submissions already in
    the pipeline are treated.  A particular point which seems
    unclear to many observers (and of concern to the
    pharmaceutical industry) is paragraph (5) which states that
    the eight year protection period does not apply "if the
    innovative drug is not being marketed in Canada."  We expect
    that the final regulations will clarify how this will be
    applied.  However, the innovative industry's reaction to the
    data protection regulation is positive, with observers
    stating that this will not only bring Canada into compliance
    with its international obligations but will also make the
    country more competitive internationally.
    Qcountry more competitive internationally.

    ¶4.  (SBU)  The Patented Medicines (Notice of Compliance) or
    PMNOC regulation is the part of the package designed to keep
    the generic companies in the deal.  The PMNOC regulation is
    more complex than the data protection regulation, but in
    general it is intended to limit innovative drug companies'
    ability to "evergreen" drug patents, or renew patents based
    on small changes to a drug.  The PMNOC regulation attempts to
    address the unintended consequences of unclear language in
    previous regulation which required court interpretation;
    these include the "possibility that an innovator company may
    delay generic market entry by listing new and sometimes
    irrelevant patents on the basis of minor product revisions."
    In what seems to be a valuable victory for the innovative
    drug industry, however, the PMNOC's Regulatory Impact
    Assessment Statement states that dosage form patents (patents
    that focus on the form of the drug, not its chemical
    composition) deserve "special protection provided by the
    PM(NOC) regulations," adding that this is "particularly true

    OTTAWA 00002021  002 OF 002

    in the case of biologic drugs where effective administration
    of the medicinal ingredient is often dependent on the
    development of new and innovative delivery mechanisms."  The
    generic industry in Canada has not made any public statement
    on the draft regulations, although they will probably submit
    formal comments.  Our contacts also tell us that the generics
    are trying to arrange for meetings with relevant officials
    and members of parliament before the comment period ends on
    July 17.

    GOC Officials' Perspective
    ---------------------------

    ¶5.  (SBU) Our GOC contacts seem confident that these
    regulations will be finalized, with very few changes, in as
    short a period as is possible under Canada's regulatory
    process.  They describe the regulations as fair and balanced,
    and they suggest that neither the innovative nor the generic
    industry should be surprised by the regulations' content.  In
    general, this is what we are hearing from industry contacts
    as well, although industry contacts hesitate to describe
    themselves as happy with the regulations and insist that
    certain changes need to be made.  Any rhetoric about pushing
    for 10 years of data protection such as in Europe seems to be
    more a bargaining tool than an actual goal.  GOC officials
    are aware that both industries, but particularly the
    innovative industry, are eager for a package to be finalized
    and are willing to accept the compromises inherent in these
    proposed regulations.

    Domestic Political Context
    --------------------------

    ¶6.  (SBU) The current Conservative government has been more
    receptive to U.S. concerns about intellectual property
    rights, and domestically the Conservative party is less
    beholden to the generic industry, which is predominantly
    based in the greater Toronto area, a Liberal stronghold.
    (Comment:  a recent bit of much-hyped campaign scandal
    involved questionable donations to a Toronto-area Liberal
    MP--totalling C$54,000--from Apotex Inc's top two executives,
    their wives and six children.  Apotex is Canada's largest
    generic drug company.  End comment.)  The innovative drug
    companies, on the other hand, are primarily based in Quebec,
    where the Conservatives are very interested in picking up
    additional seats.  In general, this suggests that the
    generics industry, which is thought to be responsible for
    delaying progress on the 2004 proposal of the first version
    of these regulations, will not be able to delay progress on
    the new draft regulations.  The most optimistic timeframe for
    final regulations is probably the end of 2006.  As with our
    other IPR goal of amendments to the copyright act, much will
    hinge on whether another election is called in the meantime.
    An election before finalization of the regulations would at
    the very least delay them regulations and could result in yet
    another redraft.

    Visit Canada's Classified Web Site at
    http://www.state.sgov.gov/p/wha/ottawa

    WILKINS

`